Literature DB >> 23179006

Ethnic difference may contribute to the efficacy of low-dose imatinib mesylate in systemic sclerosis.

Jing Tan, Jing Wei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23179006     DOI： 10.1007/s10067-012-2123-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  14 in total

1.  Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.

Authors:  Zenshiro Tamaki; Yoshihide Asano; Masaru Hatano; Atsushi Yao; Tomohiko Kawashima; Manabu Tomita; Koichiro Kinugawa; Ryozo Nagai; Shinichi Sato
Journal:  Mod Rheumatol       Date:  2011-06-03       Impact factor: 3.023

Review 2.  CYP450 pharmacogenetics for personalizing cancer therapy.

Authors:  Ron H N van Schaik
Journal:  Drug Resist Updat       Date:  2008-05-19       Impact factor: 18.500

Review 3.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

4.  Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.

Authors:  Kazunori Ohnishi; Chiaki Nakaseko; Jin Takeuchi; Shin Fujisawa; Tadashi Nagai; Hirohito Yamazaki; Tetsuzo Tauchi; Kiyotoshi Imai; Naoki Mori; Fumiharu Yagasaki; Yasuhiro Maeda; Noriko Usui; Yasushi Miyazaki; Koichi Miyamura; Hitoshi Kiyoi; Shigeki Ohtake; Tomoki Naoe
Journal:  Cancer Sci       Date:  2012-04-16       Impact factor: 6.716

5.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Authors:  Stephane Picard; Karine Titier; Gabriel Etienne; Emmanuelle Teilhet; Dominique Ducint; Marie-Agnes Bernard; Regis Lassalle; Gerald Marit; Josy Reiffers; Bernard Begaud; Nicholas Moore; Mathieu Molimard; Francois-Xavier Mahon
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

6.  Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Authors:  Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye de Leon; Shannon Seney; Kelly Summers
Journal:  Arthritis Rheum       Date:  2011-11

Review 7.  Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.

Authors:  Li Guo; Xiao-xiang Chen; Yue-ying Gu; He-jian Zou; Shuang Ye
Journal:  Clin Rheumatol       Date:  2012-08-09       Impact factor: 2.980

8.  [Analysis of plasma trough level of imatinib in Chinese CML patients].

Authors:  Li Zhou; Fan-yi Meng; Jie Jin; Qing-shu Zeng; Xin Du; Xiao-jun Huang; Zhi-xiang Shen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2012-03

9.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Authors:  Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Authors:  Robert F Spiera; Jessica K Gordon; Jamie N Mersten; Cynthia M Magro; Mansi Mehta; Horatio F Wildman; Stacey Kloiber; Kyriakos A Kirou; Stephen Lyman; Mary K Crow
Journal:  Ann Rheum Dis       Date:  2011-03-11       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.